Abstract | BACKGROUND/AIMS: METHODS: RESULTS: The duration of adefovir administration was 5.5-18 (median, 15.5) months. The median values of serum AST and ALT levels were significantly reduced from 86+/-80 IU/L and 140+/-103 IU/L, respectively before the adefovir administration to 42+/-19 IU/L and 38+/-33 IU/L after 2 months of administration. This trend of improved liver function persisted throughout the follow-up period. HBeAg seroconversion was achieved in 4 of 10 patients (40%) and HBsAg seroconversion was observed in 1 of 10 patients (10%). HBV DNA levels have decreased to undetectable levels by hybridization assay in 6 of 7 patients within the first 2 months of therapy. Nephrotoxicity and hypophosphatemia were not found in all of these patients. CONCLUSIONS: Based on this preliminary result, adefovir dipivoxil seems to be an effective and safe antiviral agent leading to viral inhibition and clinical improvement in post-LT patients with recurrent or de novo HBV infection.
|
Authors | Keon Kuk Kim, Ki Hun Kim, Shin Hwang, Chul Soo Ahn, Deok Bog Moon, Tae Yong Ha, Sung Gyu Lee |
Journal | The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
(Korean J Gastroenterol)
Vol. 45
Issue 3
Pg. 174-80
(Mar 2005)
ISSN: 1598-9992 [Print] Korea (South) |
PMID | 15778544
(Publication Type: English Abstract, Journal Article)
|
Chemical References |
- Antiviral Agents
- Organophosphonates
- Reverse Transcriptase Inhibitors
- Lamivudine
- Adenine
- adefovir dipivoxil
|
Topics |
- Adenine
(administration & dosage, analogs & derivatives)
- Adult
- Antiviral Agents
(administration & dosage)
- Drug Therapy, Combination
- Female
- Hepatitis B, Chronic
(drug therapy)
- Humans
- Lamivudine
(administration & dosage)
- Liver Transplantation
- Male
- Middle Aged
- Organophosphonates
(administration & dosage)
- Recurrence
- Reverse Transcriptase Inhibitors
(administration & dosage)
|